Seasonal respiratory syncytial virus prophylaxis based on predetermined dates versus regional surveillance data

Pediatric Infectious Disease Journal

Volumn 32, Issue 9, 2013, Pages

  Paes, Bosco A ^a   Craig, Carole ^b   Pigott, Wendy ^b   Latchman, Andrew ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b Public Health Services   (Canada)

Author keywords

Palivizumab; Respiratory syncytial virus; Seasonal prophylaxis; Timing

Indexed keywords

PALIVIZUMAB;

ADOLESCENT; ADULT; ARTICLE; CANADA; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; EXPLORATORY RESEARCH; HOSPITAL ADMISSION; HUMAN; INFANT; INFECTION PREVENTION; LABORATORY AUTOMATION; LOCAL FIXED DATE PROPHYLAXIS METHOD; LOCAL PROSPECTIVE PROPHYLAXIS METHOD; MAJOR CLINICAL STUDY; METHODOLOGY; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROVINCIAL PROPHYLAXIS METHOD; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SCHOOL CHILD; SEASONAL RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEASONAL VARIATION; TIME; TREATMENT DURATION; YOUNG ADULT;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGICAL MONITORING; FEMALE; GEOGRAPHY; HUMANS; MALE; ONTARIO; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; TIME FACTORS;

EID: 85047686737     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31829479d3     Document Type: Article

References (14)

1. Mullins JA, Lamonte AC, Bresee JS, et al. Substantial variability in community respiratory syncytial virus season timing. Pediatr Infect Dis J. 2003;22:857-862.
2. Light M, Bauman J, Mavunda K, et al. Correlation between respiratory syncytial virus (RSV) test data and hospitalization of children for RSV lower respiratory tract illness in Florida. Pediatr Infect Dis J. 2008;27:512-518.
3. Chi H, Chang IS, Tsai FY, et al. Epidemiological study of hospitalization associated with respiratory syncytial virus infection in Taiwanese children between 2004 and 2007. J Formos Med Assoc. 2011;110:388-396.
4. Turkish Neonatal Society. The seasonal variations of respiratory syncytial virus infections in Turkey: a 2-year epidemiological study. Turk J Pediatr. 2012;54:216-222.
5. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
6. Feltes TF, Cabalka AK, Meissner HC, et al.; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamic ally significant congenital heart disease. J Pediatr. 2003;143:532-540.
7. Saez-Llorens X, Moreno MT, Ramilo O, et al.; MEDI-493 Study Group. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004;23:707-712.
8. Subramanian KN, Weisman LE, Rhodes T, et al.; MEDI-493 Study Group. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 1998;17:110-115.
9. Robbie GJ, Zhao L, Mondick J, et al. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56:4927-4936.
10. Centers for Disease Control and Prevention. Respiratory syncytial virus activity - United States, July 2008-December 2009. MMWR Morb Mortal WklyRep. 2010;59:230-233.
11. Panozzo CA, Stockman LJ, Curns AT, et al. Use of respiratory syncytial virus surveillance data to optimize the timing of immunoprophylaxis. Pediatrics. 2010;126:ell6-e123.
12. Law B J, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23:806-814.
13. Wang EL, Law BJ, Stephens D PICNIC prospective study of risk factors and outcomes in patients hospitalized with RSV LRTI. Pediatrics. 1995;126:212-219.
14. Schanzer DL, Langley JM, Tarn TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J. 2006;25:795-800.